Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats

International Journal of Cancer

Volumn 110, Issue 1, 2004, Pages 70-75

  Sinibaldi Vallebona, Paola ^a   Rasi, Guido ^b   Pierimarchi, Pasquale ^b   Bernard, Paola ^b   Guarino, Enrico ^b   Guadagni, Fiorella ^c   Garaci, Enrico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CNR   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer vaccine; Liver metastasis; Peptide

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; CSH 275; FREUND ADJUVANT; NONAPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CELL STRAIN; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; LIVER METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLENIC VEIN; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; OLIGOPEPTIDES; RATS; RATS, INBRED STRAINS; VACCINATION;

EID: 1942452253     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20063     Document Type: Article

References (53)

1. Pardoll DM. Therapeutic vaccination for cancer. Clin Immunol 2000; 95:44-62.
2. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nature Rev Cancer 2002;2:1-7.
3. Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Castrati G, Dellabona P. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 2000;165:2651-6.
4. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805-18.
5. Weber J. Peptide for cancer. Cancer Invest 2002;20:208-21.
6. Bellone M, Iezzi G, Imro MA, Protti MP. Cancer immunotherapy: synthetic and natural peptides in balance. Immunol Today 1999;20: 457-62.
7. Bona CA, Casares S, Brumeanu TD. Towards development of T-cell vaccines. Immunol Today 1998;19:126-33.
8. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302.
9. Kaufman HL, Schlom J. Vaccine for colon cancer. In: Stern PL, Beverly PLC, Carroll MW, eds. Cancer vaccines and immunotherapy. Cambridge: Cambridge University Press, 2000. 107-34.
10. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J. Phase 1 trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-65.
11. Steele TA. Recent developments in the virus therapy of cancer. Proc Soc Exp Biol Med 2000;223:18-26.
12. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997; 186:645-53
13. Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP, and MHC class I expression and their upregulation by IFN-γ. Scand J Immunol 1997;46:625-32
14. Jamasbi RJ, Wan X, Stoner GD. Epitope masking of rat esophageal carcinoma tumor-associated antigen by certain coexisting glycolipid and phospholipid molecules: a potential mechanism for tumor cell escape from the host immune responses. Cancer Immunol Immunother 1994;38:99-106.
15. Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin Oncol 2000;27:221-33.
16. Semino C, Martini L, Queirolo P, Cangemi G, Costa R, Alloisio A, Ferlazzo G, Sertoli MR, Reali UM, Ratto GB, Melioli G. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. Anticancer Res 1999;19:5645-9.
17. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:269-70.
18. Pawelec G, Engel A, Adibzadeh M. Prerequisites for the immunotherapy of cancer. Cancer Immunol Immunother 1999;48:214-7.
19. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997; 9:681-3.
20. Van den Eynde B, Van Der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
21. Guadagni F, Graziano P, Roselli M, Mariotti S, Bernard P, Sinibaldi-Vallebona P, Rasi G, Garaci E. Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis. Am J Pathol 1999;154:993-9.
22. Rasi G, Sinibaldi-Vallebona P, Serafino A, Bernard P, Pierimarchi P, Guarino E, Faticanti-Scucchi L, Graziano P, Guadagni F, Garaci E. A new tumor-associated antigen (TLP) is naturally expressed in rat DHD-K12 colorectal tumor cells. Int J Cancer 2000;85:540-4.
23. Rasi G, Silecchia G, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, Tremiterra S, Garaci E. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 1994; 57:701-5.
24. Silecchia G, Guarino E, Sinibaldi-Vallebona P, Pierimarchi P, Restuccia A, Spaziani E, Bernard P, Tuthill C, Garaci E, Rasi G. Efficacy of repeated cycles of chemo-immunotherapy with thymosin α1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunol Immunother 1999;48:172-8.
25. Auerbach R, Morissey LW, Sidky YA. Regional difference in the incidence and growth of mouse tumors following intradermal or subcutaneous inoculation. Cancer Res 1978;38:1739-44.
26. Hsu SM, Raine D, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabelled antibody (PA) procedures. J Histochem Cytochem 1981;29:577-80.
27. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002;38:1023-33.
28. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Moller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 2001;98:13255-60.
29. Hellstrom KE, Hellstrom I. Principles of tumor immunity: tumor antigens. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. The biologic therapy of cancer. Philadelphia: Lippincott. Williams & Wilkins, 2000.
30. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58:143-75.
31. Bellone M, Iezzi G, Martin-Fontecha A, Rivolta L, Manfredi AA, Protti MP, Freschi M, Dellabona P, Casorati G, Rugarli C. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J Immunol 1997;158:783-9.
32. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;41:380-4.
33. Abrams SI, Hodge JW, McLaughlin JP, Steinberg SM, Kantor JA, Schlom J. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. J Immunother 1997;20:48-59.
34. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
35. Chen L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today 1998;19:27-30.
36. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Rev Immunol 2002;3: 999-1005.
37. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
38. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999;154:745-54.
39. + T cells by a single peptide with dual MCH class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002;62:3630-5.
40. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-6.
41. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002;2:251-62.
42. Sinibaldi Vallebona P, Pierimarchi P, Moroni G, Serafino A, Fuggetta MP, Tuthill C, Rasi G. Thymalfasin up-regulates tumor antigen expression in colorectal cancer cells. Tumour Biol 2002; 23:45.
43. Herlyn D, Somasundaram R, Li W, Jacob L. Animal models of human-derived cancer vaccines. Cell Biophys 1995;27:15-30.
44. Greenberg NM, De Mayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-43.
45. Hendrickson EA. The SCID mouse: relevance as an animal model system for studying human disease. Am J Pathol 1993;143: 1511-22.
46. Spicer AP, Parry G, Patton S, Gendler SJ. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1 reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domain and a loss of minisatellite polymorphism. J Biol Chem 1991;266:15099-109.
47. Genne P, Olsson NO, Caignard A, Oriol R, Bara J, Hammann A, Martin F. Histological reactivity of a monoclonal antibody against rat colon cancer cells on human and rat normal gut and colonic tumours. Virchows Arch A Pathol Anat Histopathol 1992;420:233-42.
48. + T cell epitope from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000;165:1153-9.
49. McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996: 56:2361-7.
50. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccine. Blood 1996;88:202-10.
51. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune response and antitumor effects. Cancer Res 2001;61:4497-505.
52. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J. Phase 1 trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-65.
53. + progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.